Speaker

Dr. Ricky Chiu is a pioneering biomedical engineer, inventor, entrepreneur, and educator devoted to advancing diagnostic technology and global health. As Founder and CEO of PHASE Scientific, Dr. Chiu developed PHASiFY™, a patented liquid-phase extraction platform that redefines sensitivity in liquid biopsy and infectious disease diagnostics, enabling more accurate and accessible testing for cancer and infectious diseases. His work includes leading the development of the worlds first urine DNA-based HPV test for non-invasive cervical cancer screening, which leverages patented technology for highly accurate results and broad impact on women’s health globally. During the COVID-19 pandemic, Dr. Chiu led teams in developing and distributing high-efficiency RNA extraction kits and rapid antigen tests, supporting mass testing in Hong Kong and globally. With over 55 granted patents, successful regulatory approvals, and collaborations across Asia and the U.S., Dr. Chiu has established PHASE Scientific as an international innovator in diagnostics. He is also an Adjunct Associate Professor at the Chinese University of Hong Kong, where he promotes innovation and talent development through academic engagement, lectures, and hands-on industry-academia initiatives.

Dr. Qu Jian, M.D., Ph.D., is an Associate Professor, Ph.D. Supervisor, and Deputy Chief Pharmacist at the Second Xiangya Hospital of Central South University. A Yale-trained pharmacologist (Ph.D. in Pharmacology, CSU-Yale Joint Program), he serves on key national committees including the Youth Committee of the Chinese Pharmacological Society and the Clinical Pharmacy Branch of the China Association of Gerontology and Geriatrics. His editorial roles include reviewing forCancer LettersandCNS Neuroscience & Therapeuticsand serving on the Editorial Board ofCancer Drug Resistance. Dr. Qu’s research focuses onepigenetic pharmacology, pharmacogenomics, and personalized medicine, with 94 SCI publications (62 as first/corresponding author) in elite journals such asMolecular CancerandJournal of Experimental & Clinical Cancer Research, including 6 papers with IF > 10 (peak IF: 33.9). He leads 9 major grants (NSFC, Hunan Provincial Foundation) and contributes to national initiatives like the “863 Program” and “Key New Drug Creation and Manufacturing Program,” driving innovations in precision drug therapy.

Jinghua Li is an Associate Professor at the Faculty of Health Sciences, University of Macau. Her research focus on developing mathematical and statistical models to assess the epidemiological impact and cost-effectiveness of health interventions for infectious diseases. She has received the First Prize in the Educational Achievement Award from Guangdong Province Society for Academic Degrees and Graduate Education (as the first completer) and led a Guangdong Provincial Graduate Demonstration Course. She has served as principal investigator on projects funded by the National Natural Science Foundation of China, the Guangdong Natural Science Foundation, and the China Medical Board. She has published over 100 SCI/SSCI papers in journals such as The Lancet Regional Health–Western Pacific and eClinicalMedicine, with an H-index of 24. The dynamic intervention assessment tools she developed have been widely applied in both domestic and international cities. She has served as a council member of the China Health Policy and Management Society, is an active member of the Public Health and Preventive Medicine Branch of the China International Exchange and Promotive Association for Medical and Health Care, and is a recipient of the Early Career Award from the International Society of Behavioral Medicine.

Dr. Yuanyu Huang, a tenured professor at Beijing Institute of Technology, has been recognized as a national-level young talent and a leading figure in Beijing and Suzhou, and is ranked among the top 2% of scientists worldwide as released by Elsevier. His research focuses on nucleic acid drugs and vaccines, with over 70 papers published as corresponding author in journals such as Nat Rev Bioeng, Sci Adv, Nat Commun, STTT, and Adv Mater. He has authored more than 120 papers in total and filed 60 patents, of which around 20 have been granted. His accolades include being named a Forbes China Industry Leader, RNA Therapy Rising Star, Capital Frontier Academic Achievement awardee, and receiving First-Class Natural Science Awards from Beijing (9/12) and Guangxi (5/6). He serves as associate editor for Exploration and Mol Ther, advisory board member for Trends Mol Med, and editor for Chin Chem Lett and other journals. Dr. Huang leads the development of the siRNA drug RG002C0106, which entered Phase II trials in China in August 2025.

Professor Lyu Aiping is the Vice-President (Research and Development) and Dr. Kennedy Y.H. Wong Endowed Professor in Chinese Medicine at Hong Kong Baptist University. He was elected as a Foreign Member of the Academia Europaea in 2022, recognizing his sustained excellence in systems medicine. 

Professor Lyu’s research bridges Chinese Medicine and Western medicine through the lens of systems medicine, combining advanced techniques in life sciences and data sciences. He is interested in the novel re-classification of rheumatoid arthritis. His research has further delved into the dynamics of network biomarkers for re-classification and the interaction of combined drugs for precise treatment.

Before joining Hong Kong Baptist University, Professor Lyu was the Executive Director (Legal Representative) of the Institute of Basic Research in Clinical Medicine at the China Academy of Chinese Medical Sciences (CACMS). He has since been actively involved in standardization of Chinese Medicine and strategic planning on the Chinese Medicine development in China.

Professor Lyu’s contributions to academia are substantial, with 600 academic papers published in leading journals such as Nature Medicine, Nature Communications, and Briefings in Bioinformatics, covering a wide spectrum of integrative medicine. His research innovation has led to the award of more than 60 patents.

Dr. Tang Naping is the Director of Toxicology Business Unit at InnoStar, with over 16 years of experience in toxicology research. Dr. Tang serves as a Standing Committee Member of the Safety Pharmacology Society, Chinese Pharmacological Society (CSPS), and a Council Member of the Shanghai Society of Toxicology. He has been awarded the Natural Science Award, Second Class, from the Ministry of Education, and the Shanghai Science and Technology Award, Second Prize. As the first or corresponding author, he has published 18 SCI-indexed papers.

Dai Hongbin, a senior economist, is currently the Vice Chairman of Jiangsu Hengrui Pharmaceutical Co., Ltd. He graduated from Zhongnan University of Economics and Law in 2000 with a Bachelor of Laws and a Bachelor of Economics. From 2008 to 2011, he studied at Wuhan University, receiving a Master of Management. He graduated from China Pharmaceutical University in 2024 with a Doctor of Science. He has worked at Jiangsu Hengrui Pharmaceutical Co., Ltd. since July 2000. He is a member of the Jiangsu Provincial Committee of the Chinese People’s Political Consultative Conference, Vice President of the China Pharmaceutical Industry Association, Vice President of the China Pharmaceutical Innovation Promotion Association, an expert in Shanghai’s three leading industry mother funds appointed by the Shanghai Municipal Government, and a member of the first Listing Committee of the Shanghai Stock Exchange’s Science and Technology Innovation Board.

Xuerui Yang’s research group, established in 2012 at Tsinghua University, uses multi-disciplinary approaches for mining of the multi-omics data and dissection of the multi-level gene regulatory programs. He has been particularly interested in the complex world of RNA, such as the post-transcriptional RNA regulation circuits, the translational regulation, and the non-coding RNA functions, under the contexts of complex diseases such as cancer. Dr. Yang’s group has developed a series of bioinformatics algorithms, which in turn provided novel biological insights and led to discoveries of critical translation regulation mechanisms, key regulatory RNAs for normal cell development and tumorigenesis, and noncanonical machineries of post-transcriptional RNA splicing, decay, and modifications.

Dr. Wang Tong is the Principal Investigator (PI) of the School of Life Sciences, Tsinghua University, Tsinghua University-Peking University Joint Center for Life Sciences (CLS) and Beijing Frontier Research Center for Biological Structures. He received Ph.D. degree at Tsinghua University and has research experience as a visiting scholar at Harvard University and work experience at Microsoft Research.

His main research directions include AI-driven biomolecular dynamics simulation, machine learning force fields, molecular structure representation learning, and computer-aided drug discovery. As the primary project leader, he proposed the AI2BMD dynamics simulation program, which has brought protein dynamics to ab initio accuracy, achieving “Top Ten Advances in Chinese Bioinformatics in 2024”. He also led his team to win the championship in the first Global AI Drug Discovery Competition.

Over the past five years, he has published more than 30 papers as first author or corresponding author in journals such as Nature, Nature Machine Intelligence, Nature Communications, and Cell Research, and holds more than ten patents in China and the United States.

Yi Wang is a Partner at Legend Star, where he leverages emerging technologies to address unmet medical needs and unlock health-economic value. Specializing in early-stage venture incubation, he focuses on the intelligent and robotic transformation of medical devices and has played a pivotal role in the growth of innovative companies such as Edge Medical, Longwood Valley MedTech, DeepWise, Union Strong and Healinno Tech. Prior to Legend Star, Yi held business-development and clinical-translation roles at global medicare firms including Johnson & Johnson and 3M.